NASDAQ:MDVN

(MDVN) (MDVN) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$81.44
$81.44
50-Day Range
N/A
52-Week Range
$26.41
$81.48
Volume
N/A
Average Volume
3.55 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MDVN stock logo

About (MDVN) Stock (NASDAQ:MDVN)

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.

MDVN Stock News Headlines

Notable ETF Outflow Detected - HYLB
55x Gains Instead of 9x Gains
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Medivation Alzheimer's Drug Fails Pivotal Study
55x Gains Instead of 9x Gains
We’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-up before it’s too late. It’s urgent because it’s what we consider “The #1 Crypto for the AI World.”
Core Medalist ETFs
The Connor Phillips Show
Medivation Stock Hits New 52-Week High (MDVN)
Medivation (MDVN) Stock Surges, Will Explore Sale
See More Headlines
Receive MDVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (MDVN) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/09/2016
Today
5/05/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MDVN
CUSIP
58501N10
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

MDVN Stock Analysis - Frequently Asked Questions

How were (MDVN)'s earnings last quarter?

(MDVN) (NASDAQ:MDVN) posted its quarterly earnings results on Tuesday, August, 9th. The biopharmaceutical company reported $0.29 EPS for the quarter, topping the consensus estimate of $0.27 by $0.02. The biopharmaceutical company earned $206 million during the quarter, compared to analysts' expectations of $214.52 million. The company's quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.58 EPS.

What other stocks do shareholders of (MDVN) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other (MDVN) investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), (KITE) (KITE), Array Technologies (ARRY), Freeport-McMoRan (FCX) and

This page (NASDAQ:MDVN) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners